Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 212.08
OPXA's Cash to Debt is ranked higher than
54% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. OPXA: 212.08 )
Ranked among companies with meaningful Cash to Debt only.
OPXA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 13.29 Max: No Debt
Current: 212.08
Equity to Asset 0.63
OPXA's Equity to Asset is ranked lower than
56% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPXA: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
OPXA' s Equity to Asset Range Over the Past 10 Years
Min: -1246  Med: 0.25 Max: 0.78
Current: 0.63
-1246
0.78
Interest Coverage No Debt
OPXA's Interest Coverage is ranked higher than
92% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPXA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPXA' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -20.74
M-Score: 19.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -326.89
OPXA's Operating margin (%) is ranked lower than
65% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. OPXA: -326.89 )
Ranked among companies with meaningful Operating margin (%) only.
OPXA' s Operating margin (%) Range Over the Past 10 Years
Min: -1184.59  Med: -1062.82 Max: -326.89
Current: -326.89
-1184.59
-326.89
Net-margin (%) -324.97
OPXA's Net-margin (%) is ranked lower than
66% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. OPXA: -324.97 )
Ranked among companies with meaningful Net-margin (%) only.
OPXA' s Net-margin (%) Range Over the Past 10 Years
Min: -1314.6  Med: -1248.97 Max: -324.97
Current: -324.97
-1314.6
-324.97
ROE (%) -98.89
OPXA's ROE (%) is ranked lower than
81% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. OPXA: -98.89 )
Ranked among companies with meaningful ROE (%) only.
OPXA' s ROE (%) Range Over the Past 10 Years
Min: -654.63  Med: -107.19 Max: -32.36
Current: -98.89
-654.63
-32.36
ROA (%) -65.37
OPXA's ROA (%) is ranked lower than
78% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. OPXA: -65.37 )
Ranked among companies with meaningful ROA (%) only.
OPXA' s ROA (%) Range Over the Past 10 Years
Min: -345.19  Med: -85.56 Max: -24.27
Current: -65.37
-345.19
-24.27
ROC (Joel Greenblatt) (%) -1154.59
OPXA's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. OPXA: -1154.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPXA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2807.79  Med: -994.37 Max: -410.49
Current: -1154.59
-2807.79
-410.49
EBITDA Growth (3Y)(%) -16.50
OPXA's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. OPXA: -16.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPXA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -37.4 Max: 44.6
Current: -16.5
0
44.6
EPS Growth (3Y)(%) -16.70
OPXA's EPS Growth (3Y)(%) is ranked lower than
64% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. OPXA: -16.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPXA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -38.1 Max: 51.8
Current: -16.7
0
51.8
» OPXA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OPXA Guru Trades in Q3 2015

Jim Simons 77,389 sh (-79.14%)
» More
Q4 2015

OPXA Guru Trades in Q4 2015

Jim Simons 135,289 sh (+74.82%)
» More
Q1 2016

OPXA Guru Trades in Q1 2016

Jim Simons 148,189 sh (+9.54%)
» More
Q2 2016

OPXA Guru Trades in Q2 2016

Jim Simons 169,089 sh (+14.10%)
» More
» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CLCS, NAS:MRNS, NAS:ICCC, NAS:HTBX, OTCPK:QBIO, OTCPK:LVCLF, NAS:APTO, NAS:PULM, NAS:SBOT, OTCPK:CSBTF, OTCPK:FENCF, NAS:CERU, NAS:CUR, NAS:ABIO, OTCBB:DDRT, NAS:CLBS, NAS:ONCS, NAS:VTGN, NAS:ORPN, OTCPK:PTGEF » details
Traded in other countries:P6NP.Germany,
Opexa Therapeutics Inc is engaged in developing personalized immunotherapy to treat illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica. These therapies are based on proprietary T-cell technology.

Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.

Ratios

vs
industry
vs
history
Forward P/E 7.00
OPXA's Forward P/E is ranked higher than
90% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. OPXA: 7.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.27
OPXA's P/B is ranked lower than
63% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. OPXA: 5.27 )
Ranked among companies with meaningful P/B only.
OPXA' s P/B Range Over the Past 10 Years
Min: 1.34  Med: 2.72 Max: 11.14
Current: 5.27
1.34
11.14
P/S 10.10
OPXA's P/S is ranked higher than
56% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. OPXA: 10.10 )
Ranked among companies with meaningful P/S only.
OPXA' s P/S Range Over the Past 10 Years
Min: 4.06  Med: 13.9 Max: 77.02
Current: 10.1
4.06
77.02
Current Ratio 2.34
OPXA's Current Ratio is ranked lower than
71% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. OPXA: 2.34 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.15 Max: 13.24
Current: 2.34
0.01
13.24
Quick Ratio 2.34
OPXA's Quick Ratio is ranked lower than
66% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OPXA: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.15 Max: 13.24
Current: 2.34
0.01
13.24
Days Sales Outstanding 7.29
OPXA's Days Sales Outstanding is ranked higher than
89% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. OPXA: 7.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPXA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.29
Current: 7.29
0
7.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -70.10
OPXA's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. OPXA: -70.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPXA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -263.4  Med: -39.4 Max: 0
Current: -70.1
-263.4
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.26
OPXA's Price/Net Cash is ranked lower than
55% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. OPXA: 7.26 )
Ranked among companies with meaningful Price/Net Cash only.
OPXA' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 6.49 Max: 217.12
Current: 7.26
1.31
217.12
Price/Net Current Asset Value 6.61
OPXA's Price/Net Current Asset Value is ranked lower than
56% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. OPXA: 6.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPXA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.19  Med: 4.99 Max: 122.88
Current: 6.61
1.19
122.88
Price/Tangible Book 5.27
OPXA's Price/Tangible Book is ranked lower than
55% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. OPXA: 5.27 )
Ranked among companies with meaningful Price/Tangible Book only.
OPXA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.75  Med: 3.58 Max: 119.82
Current: 5.27
0.75
119.82
Price/Median PS Value 0.72
OPXA's Price/Median PS Value is ranked higher than
72% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. OPXA: 0.72 )
Ranked among companies with meaningful Price/Median PS Value only.
OPXA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 1.03 Max: 5.54
Current: 0.72
0.37
5.54
Earnings Yield (Greenblatt) (%) -40.42
OPXA's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. OPXA: -40.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPXA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -43.5  Med: 1806.5 Max: 5801.3
Current: -40.42
-43.5
5801.3

More Statistics

Revenue (TTM) (Mil) $2.90
EPS (TTM) $ -1.33
Beta1.25
Short Percentage of Float3.08%
52-Week Range $1.69 - 5.10
Shares Outstanding (Mil)7.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 15 13 5
EPS ($) 0.61 -0.42 -0.76
EPS w/o NRI ($) 0.61 -0.42 -0.76
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
OPEXA THERAPEUTICS, INC. Financials Aug 19 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : August 12, 2016 Aug 12 2016
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 11 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2016
OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 11 2016
Q2 2016 Opexa Therapeutics Inc Earnings Release - After Market Close Aug 11 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter... Aug 09 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter... Aug 09 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : July 19, 2016 Jul 19 2016
5 Top Biotech Performers of 2016 Jul 01 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 18 2016
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2016
OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 12 2016
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016... May 10 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016... May 10 2016
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its... Apr 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)